Autologous stem cell-based therapy for sickle cell leg ulcer: a pilot study

Area of Science:

• Hematology
• Regenerative Medicine
• Wound Healing

Background:

• Recurrent chronic leg ulcers are severe complications of sickle cell disease (SCD).
• Current treatments for sickle cell leg ulcers (SCLU) present challenges.
• Stem cell therapy offers a potential new therapeutic avenue for chronic wounds.

Purpose of the Study:

• To evaluate the safety and feasibility of bone marrow mononuclear cell (BMMC) implantation in patients with SCLU.
• To assess ulcer closure, recurrence rates, and local pain following BMMC treatment.
• To investigate the frequency of progenitor stem cells in SCLU patients.

Main Methods:

• A prospective pilot study involving 23 SCLU patients.
• BMMC were administered to patients, and outcomes were monitored over a 6-month follow-up period.
• Analysis included ulcer healing, pain assessment, and quantification of specific progenitor stem cell populations (CD34CD45low and fibroblast colony-forming units).

Main Results:

• BMMC implantation was successfully performed in all 23 patients with no serious adverse events.
• Significant improvement in ulcer pain was observed in 91.3% of patients.
• Complete healing was achieved in 29.2% of the treated ulcers.
• Progenitor stem cell frequency was notably reduced in SCLU patients compared to SCD patients without ulcers.

Conclusions:

• BMMC implantation is a safe and feasible procedure for treating SCLU.
• The treatment demonstrated favorable outcomes regarding pain reduction and ulcer healing.
• Further controlled clinical trials are warranted to confirm these findings.